Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling
These findings indicate that metformin synergistically enhances the antitumor activity of alpelisib in HER2-positive breast cancer by inhibiting oncogenic signaling and stemness pathways. Beyond its metabolic benefit in mitigating hyperglycemia, metformin may potentiate PI3K-targeted therapies, supporting further preclinical and clinical evaluation of this combination strategy.
Authors
- Peijia Niu
- Lexia Chen
- Xiaohe Yang (ORCID: https://orcid.org/0000-0002-5239-2451)
- Yujie Shi (ORCID: https://orcid.org/0000-0002-7610-0433)
- Qiong Cheng (ORCID: https://orcid.org/0000-0003-3464-5870)
- Yi Ming Weng (ORCID: https://orcid.org/0000-0001-9716-7576)
Institutions
- North Carolina Central University (US)
- Zhengzhou Central Hospital (CN)
- Zhengzhou People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fonc.2025.1631415
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00